Sector News

WuXi to build dedicated vaccine facility, but who’s the client?

May 21, 2019
Life sciences

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a contract that should produce $150 million a year for 20 years. It just didn’t identify the client.

The Chinese CDMO Monday announced the letter of intent, saying WuXi Vaccines will build a vaccine manufacturing facility that will be able to handle substance and drug product manufacturing and will include quality control labs. It said it has estimated the value of the 20-year manufacturing contract at more than $3 billion.

“Vaccine CDMO is one of the next growth areas for WuXi Biologics,” WuXi Biologics CEO Chris Chen said in a statement.

While WuXi didn’t identify the partner, it offered a couple clues. It said the site will manufacture 100% of the global market of one the partner’s vaccine products, suggesting the vaccines might be intended for use outside China. Most Chinese vaccine makers only produce for the country.

Also, when WuXi Vaccines was formed last year as a joint venture between WuXi Biologics and veterinary vaccine maker Shanghai Hile Bio-Technology, WuXi said in a securities filing the venture was being formed to primarily make cancer vaccines.

Reports in the China media earlier this year said WuXi was in talks with three vaccine developers to make their products in China. But Chen at the time suggested the company might be making a play for the country’s vaccination market after regulatory reactions to scandals by Chinese makers limited their production.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.